Increased morbidity and mortality occur regularly during influenza epidemics. The exact mechanisms involved are not well defined but bacterial superinfection of influenza virus infected patients is considered to play an important role. In the present study, the effect of influenza virus infection on in vivo production of tumour necrosis factor (TNF) in response to bacterial stimuli was investigated. Release of TNF in mice infected by an aerosol of influenza virus was significant after administration of bacterial lipopolysaccharide (LPS) at 72 h, whereas administration of homologous influenza virus produced only modest amounts of TNF at 96 h. Significant production of TNF was observed 48 h after intravenous administration of infectious influenza in response to LPS but not with the homologous virus. TNF induced after influenza virus infection could be blocked by a specific murine anti-TNF monoclonal antibody. Higher TNF production following aerosol influenza infection correlated with peak titres of influenza virus in the lungs of infected mice and with enhanced generation of luminol-dependent chemiluminescence.

Key words: Anti-TNF antibody, Chemiluminescence, Influenza virus, TNF

Introduction

Tumour necrosis factor α (TNFα) is a pleiotropic cytokine produced mainly by macrophages. The potent immunomodulatory properties of TNF include proliferation of B and T lymphocytes, as well as augmentation of cytotoxic T, NK cell, and neutrophil activities. In addition, TNF has been shown to synergize with other cytokines such as interferon-γ. These TNF-associated host defence mechanisms can play a pivotal role in restricting the spread of microbial pathogens.

There is, however, increasing evidence that excessive and deleterious production of TNF can be triggered during severe episodes of certain infections. Raised levels of TNF and soluble TNF receptors have been detected during human immunodeficiency virus (HIV) infection in seropositive patients. TNF has been associated with enhanced expression of nuclear factor kappa B, activation of HIV long terminal repeat and subsequent up-regulated transcription of the virus.

Production of TNF has been shown to be increased in chronic hepatitis B virus infection and clinical studies have indicated a proirritant effect of TNF at higher doses. TNF plays a major role also in the pathogenesis of the septic shock syndrome.

Production of lipopolysaccharide-induced tumour necrosis factor during influenza virus infection in mice coincides with viral replication and respiratory oxidative burst

K. N. Masihic, H. Hintelmann, K. Madaj and G. Gast

Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany

Corresponding Author

Elderly persons and those with underlying health problems have more severe illness and increased complications from influenza. Additional deaths above the normal winter increase occur regularly during influenza epidemics and are used as one of the non-virologic indicators for influenza surveillance. Excess mortality of at least 10,000 has been documented in each of the 19 epidemics in the United States from 1957 to 1986. The exact mechanisms involved in increased morbidity and mortality during influenza infection are not as yet well defined. Bacterial superinfection of influenza virus infected patients is considered to play an important role in exacerbating virus-associated pathophysiology during influenza epidemics. Influenza virus has been shown to induce the production of TNF, although the exact role of TNF during influenza infection remains unclear. Broncho-alveolar washings obtained from mice infected with influenza virus contained TNF and TNF activity was demonstrated in influenza virus infected or influenza neuraminidase treated macrophages. No attempts have been undertaken to establish whether in vivo influenza virus infection induces production of TNF in response to bacterial stimuli. The present study was conducted to investigate in vivo TNF production in response to LPS in mice admin-
istered infectious influenza by aerosol or parenteral routes.

Materials and Methods

Mice: Four- to 5-week-old female NMRI mice were obtained from the animal facility maintained by the Federal Health Office.

Pretreatment with influenza virus: Influenza A/PR/8/34 (H1N1) was grown in the allantoic cavity of 11-day embryonated eggs using standard procedures. Infectious virus was administered to mice using a 1–2 μm diameter particle aerosol of mouse-adapted influenza virus in a Middlebrook Airborne Infection Apparatus (Tri-R Instruments, Rockville Center, USA). A 6 ml suspension of influenza virus was nebulized at 20°C using a venturi nebulizer. The LD₅₀ for mice was 10⁻⁴.⁵ by the intranasal and 10⁻².⁷ by the aerosol route. Some groups of animals received 10 – 1 000 haemagglutinin units of infectious virus by the intravenous (i.v.) route.

Determination of influenza virus in lungs: Lung virus titres were determined at various time intervals after influenza aerosol infection. Lungs from five mice were removed intact, rinsed in sterile saline and quickly frozen at −70°C. After thawing, lungs were homogenized in a tissue grinder in 1 ml of cold MEM medium containing 10% fetal calf serum and antibiotics for each lung. Ten-fold dilutions of each supernatant obtained after centrifugation of the lung homogenate were inoculated in 25 μl amounts into confluent monolayers of MDCK cells in 24-well microtitre plates. Quadruplicate cultures were set up for each dilution. The virus titre was determined 2 days later by haemadsorption with chicken red blood cells. The results are expressed as log₁₀ of 50% tissue culture infective doses (TCID₅₀) calculated according to the Reed and Muench method.

Treatment with lipopolysaccharide (LPS): Mice pretreated with influenza virus were administered 25 μg of phenol–chloroform–petroleum ether extracted LPS from Salmonella minnesota (Sigma Chemical Company) by the intravenous route at various time intervals. Animals were bled from the retro-orbital plexus 1.5–2 h later and sera were stored at −20°C.

TNF bioassay: TNF activity in serum samples was determined by a standard fibroblast cytotoxicity assay. Briefly, 100 μl of 2.5 × 10⁵ cells per ml of a sensitive L929 cell line were added to 96-well microtitre plates (NUnc) and incubated overnight to form monolayers. Various dilutions of test samples and 1 μg of actinomycin D (Sigma Chemical Company) dissolved in Eagle’s minimum essential medium were added to wells, each in a volume of 100 μl. Plates were incubated for 18 h at 37°C in the presence of 5% CO₂. Following incubation, the wells were aspirated and stained with 0.05% crystal violet in 20% ethanol for 15 min. After thoroughly washing the cells with distilled water, the plates were air dried. The stained cells were solubilized by adding 250 μl of ethylene glycol monomethyl ether to each well. The plates were shaken in the dark for 1 h and the optical density was read at 600 nm in a Microplate Reader MR700 spectrophotometer (Dynatech). The percentage cytotoxicity was determined. Units of TNF were calculated by plotting the regression lines of the log of the reciprocal dilution of the test sample vs. the percentage cytotoxicity. One unit equals the highest reciprocal of the supernatant dilution which resulted in 50% lysis.

Treatment with anti-TNF monoclonal antibody: Test dilutions of 1/5 serum samples in a volume of 50 μl were mixed thoroughly with the same volume of murine anti-TNF monoclonal antibody (kindly provided by BASP, Ludwigshafen, Germany) containing 125 units. Test serum alone, anti-TNF alone and normal mouse serum plus anti-TNF antibody were also included in the panel. Sera were incubated for 1 h at 37°C with gentle shaking every 15 min. The plates were placed for 30 min at 4°C and the TNF assay was performed as described above.

Chemiluminescence assay: Aliquots of 500 μl of spleen cell suspensions in round-bottomed vials were mixed with 10 μl of luminol at a concentration of 1 mg/ml in phosphate buffered saline containing 0.4 triethylamine and incubated at 37°C for 10 min. Chemiluminescence (CL) measurements were performed at 37°C in a specially developed Biolumat model 9505 (Berthold, Wildbad, Germany) which permits simultaneous reading of six samples. After the measurement of background for 3 min, CL was generated by addition of 10 μl of particulate stimuli zymosan (Sigma) suspended in buffered saline at a concentration of 50 mg/ml. CL was continuously monitored on a programmed microcomputer.

Statistical analysis: Results are expressed as mean ± S. D. Statistical comparison with appropriate control groups was performed using two-tailed Student's t-test.
Results

Kinetics of TNF induction in mice infected by aerosol influenza virus in response to LPS: Animals administered an aerosol of influenza virus received an injection of LPS by the i.v. route (five mice per group) after 24, 48, 72 and 96 h, and at 7 days. Sera collected 90–120 min after LPS administration were tested for the presence of TNF activity. The results presented in Fig. 1 show significant production of TNF 72 h after influenza virus infection (p < 0.0012). A low, but detectable amount of TNF was produced 96 h after influenza infection (p < 0.0027). When aerosol influenza infected mice were given an i.v. trigger with homologous influenza A/PR/8/34 virus instead of LPS, a modest amount of TNF was induced only at 96 h (p < 0.0122) as is shown in Fig. 1. The levels of TNF production in uninfected mice after i.v. injection of LPS from Salmonella minnesota were of a low magnitude when compared with the 72 h-primed influenza group, and did not exceed 52 units/ml. Similar amount of LPS from virulent Escherichia coli can induce substantial release of TNF.

The specificity of TNF induced by influenza virus was tested using an anti-TNF monoclonal antibody. TNF induced 72 h after influenza virus infection could be blocked by a specific murine anti-TNF monoclonal antibody, as is shown in Table 1.

Chemiluminescence response of mice infected by aerosol influenza virus: Animals in groups of five were infected by an aerosol of influenza virus and LPS was administered by the i.v. route at 24, 48, 72, 96 h, and at 7 days. The functional activity of macrophages was assayed by zymosan-stimulated CL which was performed at the times indicated above. The results presented in Fig. 2 show that peak CL response occurred at 72 h (p < 0.0004) followed by 96 h (p < 0.0016) time intervals after influenza virus infection. Influenza infected mice without LPS administration generated CL levels which did not differ significantly from those of uninfected controls (data not shown).

Lung virus titres in mice infected by aerosol influenza virus: The amount of virus present in the lungs was determined by titration of lung homogenates on confluent monolayers of MDCK cells. The results presented in Fig. 3 show the presence of detectable virus at all time periods tested. Infectivity titres from the lungs of mice infected by aerosol influenza virus but not treated with LPS were comparable to those obtained in the 24h group (data not shown). Peak virus titres after influenza infection were detected after 72 h and were followed by the 96 h group.
Kinetics of TNF induction after intravenous influenza virus infection in mice: Animals in groups of five were injected with 10, 100, 500 or 1000 haemagglutinin units of infectious influenza virus by the i.v. route. Forty-eight h later, animals received 25 μg of LPS or 1000 haemagglutinin units of infectious A/PR/8/34 influenza virus also by the i.v. route. In preliminary experiments, the LPS trigger, administered by the i.v. route at 24, 48, 72 and 96 h, and at 7 days, induced a significant production of TNF at 48 h after i.v. influenza administration (data not shown). The results presented in Fig. 4 show induction in a dose-dependent manner of TNF. Peak TNF titres were obtained by priming with 1000 haemagglutinin units of influenza virus (p < 0.0005). Comparable TNF amounts were present in sera of animals receiving 500 (p < 0.0001) or 100 (p < 0.0001) haemagglutinin units of influenza virus. A trigger with homologous A/PR/34 virus was not effective in inducing TNF in A/PR/8/34 virus-primed mice.

Discussion

Influenza virus infection can predispose the host to bacterial superinfection. Human and experimental animals infected with influenza have been shown to have increased incidence of bacterial infections due to diverse bacteria including Streptococcus species, Escherichia coli and Haemophilus influenzae. The results of the present study demonstrate that in vivo influenza virus infection by the natural aerosol route can prime the host for subsequent release of TNF in response to bacterial stimuli and also extend previous in vitro observations showing LPS-induced potentiation of the production of TNF from influenza virus-infected macrophages.

The role of TNF in viral infections is dichotomous, exhibiting both beneficial and deleterious activities. A variety of cell lines from diverse sources could be protected by TNF against infections by vesicular stomatitis virus, encephalomyocarditis virus, adenovirus and herpes simplex virus. On the other hand, TNF has been shown to exacerbate several other viral infections including those caused by HIV. Primary blood monocyte-derived macrophages treated with recombinant human TNF starting before or after HIV infection enhanced viral replication of both lymphocyte-tropic and macrophage-tropic strains. Recombinant TNF has been shown to activate HIV mRNAs, increase replication, and enhance syncytium formation in T-cell lines. Simian varicella virus-infected monkeys given TNF showed increased mortality, and porcine monocytes treated with TNF showed an increase of African swine fever virus production.

The kinetics of TNF production by the influenza virus exhibited a marked dependence on the time elapsed after influenza infection and administration of LPS. Significant TNF production was evident 72 h after aerosol virus infection. TNF can profoundly affect the functional capability of phagocytic cells, and has been shown to enhance the response of neutrophils to particulate stimuli, alter surface receptors and prime for enhanced production of oxygen radicals. Administration of TNF in mice can result in an increase of the percentage of splenic macrophages. In the present study, a high level of splenic cell CL activity was observed at 72 h in influenza virus-infected animals that had received LPS. It is noteworthy that the time period of enhanced CL coincides with the peak TNF pro-
duction and correlated with peak titres of influenza virus which were also detected 72 h after infection.

Influenza virus or viral components have been shown to stimulate the production of interferon-γ and IL-1. In numerous studies, TNF has been shown to synergize with other cytokines including interferon-γ. The intricate synergistic interaction between the putative cytokines released during the period of peak influenza virus production and resultant sequelae remain to be elucidated. The results of the present study suggests that the TNF response of the influenza virus infected host on the subsequent homologous influenza virus challenge is of a low magnitude. This could be a reflection of the protection afforded by primary influenza infection. In contrast, high levels of TNF were induced in influenza virus infected animals administered bacterial LPS. An understanding of the kinetics required for the influenza virus to sensitize a host for induction of TNF in response to bacterial stimuli may help define the critical period when complications could occur in institutionalized elderly patients and other persons at risk during influenza epidemics.

References

1. Kehrl J, Miller A, Fauci AS. Effect of tumor necrosis factor on mitogen-activated human B cells. J Exp Med 1987; 166:786.
2. Yokota S, Geppert EJ, Folks TM. Enhancement of antigen and mitogen-induced human T lymphocyte proliferation by tumor necrosis factor. J Immunol 1988; 140:531.
3. Ranges GR, Figat M, Estepin T, Palladini MA. Inhibition of cytotoxic T cell development by transforming growth factor-beta and reversal by recombinant tumor necrosis factor. J Exp Med 1987; 166:991.
4. Osterhaus AE, Thiele DL, Umpiy PE. Tumor necrosis factor enhances cytolytic activity of human natural killer cells. J Immunol 1987; 138:4185.
5. Klebanoff S, Vaida MA, Harfan JM, et al. Stimulation of neutrophils by tumor necrosis factor. J Immunol 1986; 136:4220-4225.
6. Fasshauer O, Rafflin MA, Carrasio L, Human gamma interferon and tumor necrosis factor exert a synergistic blockade on the replication of herpes simplex virus. J Virol 1989; 63:1595-1599.
7. Feduchi K, Alonso MA, Carrasio L, Human gamma interferon and tumor necrosis factor activates human immunodeficiency virus type 1 infection. J Immunol 1990; 145:1921-1928.
8. Metan J, Digl W, Mittunck C, et al. Antiviral effects of recombinant tumor necrosis factor. Nature 1986; 323:816-819.
9. Veyssier AK, Goddell EC. Tumor necrosis factor alpha and beta inhibit virus replication and synergize with interferon. Nature 1986; 323:819-822.
10. Metzger JF, Griffith BI, Ortiz MA, Lecadry ML, Ryan JL. Tumor necrosis factor enhances antiviral activity of human immunodeficiency virus type 1 replication in primary macrophages. J Infect Dis 1991; 163:73-82.
11. Matsuyama T, Hamamoto Y, Soma G, Mizuno D, Yamamoto N, Kobayashi C. GPC/IR7: a novel factor on cells chronically infected with human immunodeficiency virus (HIV). Enhancement of HIV replication. J Virol 1989; 63:2504-2509.
12. Moller JF, Maury J-P, Folks TM, Fauci AS, Rabinson AB. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-κB sites in the long terminal repeat. Proc Natl Acad Sci USA 1989; 86:5974-5978.
13. Lau JY, Sherman N, Nouri-Aria KT, Alexander GJ, Williams R. Increased tumor necrosis factor alpha receptor numbers in chronic hepatitis B virus infection. Hepatology 1991; 14:44-50.
14. Tracey KI, Cerati T. Tumor necrosis factor: an updated review of its biology. Critical Care Med 1996; 24(Suppl):S7-10.
15. Centers for Disease Control. Prevention and control of influenza: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1999; 48(RR-7):1-19.
16. Abramson JS, Mills EL. Depression of neutrophil function induced by viruses and its role in secondary microbial infections. Rev Infect Dis 1988; 10:326-341.
17. Vacheron F, Radetski D, Perin S, Labarre Q, Guenounou M. Production of interleukin 1 and tumor necrosis factor activities in bronchoalveolar lavages following infection of mice by influenza virus. J Gen Virol 1990; 71:677-679.
18. Sprenger H, Bacher M, Rischkowsky E, Bender A, Nain M, Gems D. Characterization of a high molecular weight tumor necrosis factor alpha mRNA in influenza A virus-infected macrophages. J Immunol 1994; 152:289-296.
19. Hourie M, Anton J-S. Stimulation of tumor necrosis factor secretion by purified influenza virus neuraminidase. Cell Immunol 1990; 129:104-111.
20. Nain M, Hinder F, Gong JH, et al. Tumor necrosis factor production of influenza A virus-infected macrophages and potentiation of lipopolysaccharides. J Immunol 1990; 145:1921-1928.
21. Metan J, Digi W, Mittunck C, et al. Antiviral effects of recombinant tumor necrosis factor. Nature 1986; 323:816-819.
22. Wong GTF, Goodcliff D. Tumor necrosis factor alpha and beta inhibit virus replication and synergize with interferons. Nature 1986; 323:819-822.
23. Millsor JF, Griffith BI, Ortiz MA, Lecadry ML, Ryan JL. Tumor necrosis factor enhances antiviral activity of human immunodeficiency virus type 1 replication in primary macrophages. J Infect Dis 1991; 163:73-82.
24. Matsuyama T, Hamamoto Y, Soma G, Mizuno D, Yamamoto N, Kobayashi C. GPC/IR7: a novel factor on cells chronically infected with human immunodeficiency virus (HIV). Enhancement of HIV replication. J Virol 1989; 63:2504-2509.
25. Folks TM, Clouse KA, Justement J, et al. Tumor necrosis factor alpha induces the expression of T-cell clone. Proc Natl Acad Sci USA 1986; 83:2365-2368.
26. Veyssier AK, Goddell EC. Tumor necrosis factor alpha enhances antiviral activity of human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells. J Infect Dis 1990; 162:331-335.
27. Espinosa P, Gonzalez JF, Viscaya E. Effect of interferon-alpha, interferon-gamma and tumor necrosis factor on African swine fever virus replication in porcine monocytes and macrophages. J Gen Virol 1988; 69:2973-2980.
28. Sprenger H, Bacher M, Rischkowsky E, Bender A, Nain M, Gems D. Characterization of a high molecular weight tumor necrosis factor alpha mRNA in influenza A virus-infected macrophages. J Immunol 1994; 152:289-296.

Received 19 January 1995; accepted in revised form 2 March 1995